Get intelligentvalue.com

Own it today or select a payment plan

Secured by Stripe

Premium Domain Name

intelligentvalue.com

intelligentvalue.com logo

is available for purchase

51 views
Visitors fromUSUS 54%·AUAU 32%·ININ 7%·GBGB 2%·FRFR 2%

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

VisaMastercardAmerican ExpressDiscoverDiners ClubJCBApple PayGoogle Pay

Is Remission Possible for Pancreatic Stage IV Cancer?

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Newport Beach, California, United States - 09-08-2022 (PR Distribution™) -

Few diseases strike greater fear in patients more than pancreatic cancer – it is one of the most lethal of all human maladies. 

 “Patients often ask if remission is possible for late-stage pancreatic cancer!” says Gregory DiRienzo, CEO of Integrative Cancer Centers of America (www.iccahelp.com). “With our response often a conditional yes, provided the patient can undergo Live Cell Tumor Profiling.”  

“So how does Live Cell Tumor Profiling have the potential to increase treatment outcomes by as high as 200%, when many conventional cancer therapies can’t,” asks DiRienzo.

“First, you must accept that all living cells have a lethal enemy – Superman has kryptonite, Nightwalkers have Dragonglass with most cancers having lethal enemies as well, typically lethal chemo’s,” says DiRienzo, “however, chemo that may kill one patient’s cancer, may not kill another’s -- even with the same diagnosis!”

Here are three examples:

  1. 2012 study of 68 colon cancer patients given “DNA targeted “therapy -- 1 of 68 patients responded favorably (1.5%).
  2. 2015 study of 27 Colon Cancer patients with the “target B-Raf mutation” – 1 of 27 patients responded favorably (4%). 
  3. 2015 study of 229 patients “Gene-Directed “vs. Physicians’ directed - time to progression:   2.3 vs 2.0 months, clearly showing “molecularly targeted agents outside their indications do not improve progression-free survival.”  

Recognizing these inherent weaknesses, Integrative Cancer Centers now offers a 7-day test that can significantly improve survival rates by analyzing that patient’s unique live cancer cells and assessing which drugs as vast as they may be, will illicit the greatest cell death for that patient, even before, during, or after first-line therapy.

“Testing cancer cells against potential drugs offer patients the opportunity to take charge of their cancers and identify those treatments that will most likely work, and; is particularly helpful in treating cancers that have been considered “untreatable,” such as pancreatic, advanced lung, and recurrent breast cancers, “ says DiRienzo, 

With over 12,500 Live Cell Tumor Profiles done to date, the below scans graphically show the favorable outcome this very metastatic cancer patient experienced after undergoing live cell tumor profiling at our affiliate cancer centers in South America in 2013. 

By the way, the patient is still very much alive. 

Media Contacts:

Company Name: ICCA
Full Name: Greg DiRienzo
Phone: 949 939 0050
Email Address: Send Email
Website: http://www.iccahelp.com

For the original news story, please visit https://www.prdistribution.com/news/is-remission-possible-for-pancreatic-stage-iv-cancer/9277852.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  253.79
+3.77 (1.51%)
AAPL  311.23
+0.97 (0.31%)
AMD  523.20
-19.32 (-3.56%)
BAC  54.17
+1.77 (3.38%)
GOOG  369.27
+13.59 (3.82%)
META  627.57
+4.59 (0.74%)
MSFT  428.05
+0.71 (0.17%)
NVDA  218.66
+3.91 (1.82%)
ORCL  236.34
+6.01 (2.61%)
TSLA  418.45
-5.25 (-1.24%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.